home All News open_in_new Read More

Continuous Biomarker Monitoring Pioneer Proton Intelligence Inc Announces a $6.95 Million Seed Raise to Initiate Human Trials for Potassium Monitoring in Patients With Kidney Disease

VANCOUVER, British Columbia & MELBOURNE, Australia — Proton Intelligence Inc., developing the first-ever Continuous Potassium Monitoring (CKM™) platform, today announced the closing of its $6.95 million USD Seed Financing round joined by SOSV, We Venture Capital, Tenmile, LongeVC, 15th Rock, Exor, and Trampoline Venture Partners. The CKM™ platform is designed to transform the management of […]


Proton Intelligence Inc. has raised $6.95 million to initiate human trials for its Continuous Potassium Monitoring (CKM™) platform. This platform aims to revolutionize the management of cardio-kidney-metabolic diseases by providing on-demand continuous data on potassium levels, a vital biomarker that is currently difficult to measure accurately. Dangerous fluctuations in potassium levels can lead to serious heart problems, and timely monitoring is critical for effective treatment and preventing life-threatening complications.


today 17 hours ago attach_file Economics
attach_file Other
attach_file Events
attach_file Other
attach_file Economics
attach_file Other
attach_file Other
attach_file Transport
attach_file Sport
attach_file Events


ID: 9836319
Add Watch Country

arrow_drop_down